(Q33874835)

29 July 2017

1 reference

title

Agents for treatment of invasive fungal infections (English)

1 reference

invasive fungal infections

29 July 2017

main subject

1 reference

Luna B

1

1 reference

29 July 2017

Drew RH

series ordinal

2

1 reference

29 July 2017

Perfect JR

series ordinal

3

1 reference

29 July 2017

publication date

1 April 2000

1 reference

Otolaryngologic Clinics of North America

29 July 2017

published in

1 reference

29 July 2017

volume

33

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

277-299

1 reference

Systemic antifungal agents. Drug interactions of clinical significance

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Amphotericin B Pharmacokinetics in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Renal magnesium wasting associated with amphotericin B therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

1 reference

7 January 2021

A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Ketoconazole therapy for endemic blastomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Antifungal Action of Amphotericin B in Combination with Other Polyene or Imidazole Antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Amphotericin B: current understanding of mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Single-dose oral fluconazole in the treatment of vaginal candidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Amphotericin-B-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Distribution and activity of amphotericin B in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Clinical pharmacokinetics of systemic antifungal drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Use of 5-fluorocytosine in patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Antibiotics that inhibit fungal cell wall development

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Adjunctive Therapy of Allergic Bronchopulmonary Aspergillosis with Itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Incidence of polyene-resistant yeasts recovered from clinical specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Itraconazole therapy in aspergillosis: study in 49 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Current strategies for treating invasive candidiasis: emphasis on infections in nonneutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Antifungal agents: chemotherapeutic targets and immunologic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Pharmacokinetics of itraconazole following oral administration to normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

The clinical pharmacokinetics of itraconazole: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Concentrations of amphotericin B in faeces and blood of healthy volunteers after the oral administration of various doses

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Empiric amphotericin B therapy in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Hepatosplenic candidiasis: successful treatment with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Invasive aspergillosis in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Antifungal therapy during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

The search for new triazole antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Distribution of doubly radiolabelled amphotericin B methyl ester and amphotericin B in the non-human primate, Macaca mulatta

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Drug interactions with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Resistance to fluconazole and amphotericin B in a patient with AIDS who was being treated for candidal esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Treatment of vaginal candidiasis with a single oral dose of fluconazole. Multicentre Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Clearance of funguria with short-course antifungal regimens: a prospective, randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Amphotericin B blunts erythropoietin response to anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Effect of salt supplementation on amphotericin B nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Six years' experience in treatment of chromomycosis with 5-fluorocytosine,

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Erythropoietin concentration in amphotericin B-induced anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Origin of differences in susceptibility of Candida krusei to azole antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

In vitro evaluation of voriconazole against some clinically important fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Strategies in the treatment of systemic fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism).

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Development of Resistance to Amphotericin B in Candida lusitaniae Infecting a Human

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Antifungal agents. Part I. Amphotericin B preparations and flucytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Fungal virulence genes as targets for antifungal chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Adverse drug reactions to systemic antifungals. Prevention and management

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Interactions in vitro between polyenes and imidazoles against yeasts

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Antifungal susceptibility testing: technical advances and potential clinical applications.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Amphotericin B-resistant yeast infection in severely immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Amphotericin B lipid complex

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Resistance of Candida species to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Inhibition of squalene epoxidase by allylamine antimycotic compounds. A comparative study of the fungal and mammalian enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Amphotericin B. Still the 'gold standard' for antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

In Vitro Studies with Combinations of 5-Fluorocytosine and Amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of < or = 100/mm3: demonstration of efficacy in a positive, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Antifungal agents. Part II. The azoles

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Problems and controversies in the management of hematogenous candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Fluconazole treatment of candidal infections caused by non-albicans Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

5-Fluorocytosine in the Treatment of Mycotic Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

In vitro interaction between amphotericin B and azoles in Candida albicans.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Special features of the clinical use of oral terbinafine in the treatment of fungal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Fluconazole in the management of fungal urinary tract infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Nonbacterial thrombotic endocarditis clinically mimicking veno-occlusive disease of the liver complicating autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Amphotericin B: an introduction

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Treatment of native valve Candida endocarditis with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Imidazoles, ketoconazole, amphotericin B, and Candida guilliermondii.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0030-6665%2800%2980005-5

7 January 2021

10.1016/S0030-6665(00)80005-5

Identifiers

DOI

0 references

1 reference